0RAM.L - Vistin Pharma ASA
| Chiusura precedente | 21,05 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,13 |
| Rapporto PE (ttm) | 0,25 |
| EPS (ttm) | 0,56 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireNotice of Annual General Meeting in Vistin Pharma ASA
Oslo, Norway, 28 April 2023 Vistin Pharma ASA (OSE: VISTIN), please find attached the call for the Annual General Meeting in Vistin Pharma, to be held on 22 May at 13:00 CEST. A physical Annual General Meeting will not be held. Instead, shareholders should authorize the Chairman of the Board. It is possible to give proxy with and without voting instructions. By using a proxy with voting instructions, the shareholders will vote on the specific issues without personal attendance. For further infor
- GlobeNewswire
Vistin Pharma ASA: Annual Report for 2022
Oslo, Norway, 27 April 2023 Please find attached the Annual Report for 2022 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year results presented on 17 February 2023. The annual report for 2022 will also be made available on www.vistin.com. ***** For further information, please contact: Alexander KarlsenCFO+47 97 05 36 21Alexander.karlsen@vistin.com Attachments 2022 Annual Report Vistin Pharma ASA Vistinpharmaasa-2022-12-31-en
- GlobeNewswire
Vistin Pharma ASA: First quarter 2023 financial results
Oslo, Norway, 27th of April 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the first quarter of 2023. Revenue in the first quarter ended at MNOK 101 compared to MNOK 33 in Q1 2022. Manufacturing from two production lines in the quarter has resulted in more volumes available for sale, compared to Q1’22 where there were an eight-week production stop due to the MEP installation. First quarter EBITDA ended at MNOK 14.1 (MNOK -18.2). EBITDA positively af
GlobeNewswireVistin Pharma ASA: Invitation to Q1 2023 conference call
Oslo, Norway, 20 April 2023 Vistin Pharma ASA will release its first quarter 2023 results on Thursday 27th of April 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day: Thursday 27th of April at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The first quarter conference call will be available via web and audio through the following access points: Webcast: https://edge
- GlobeNewswire
Vistin Pharma ASA: Fourth quarter and preliminary 2022 financial results
Oslo, Norway, 17th of February 2023 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the fourth quarter 2022 Det company enjoyed a very strong finishing quarter in 2022 with a 42% revenue and other income growth compared to last year. Revenue and other income in the fourth quarter ended at MNOK 111 compared to MNOK 78 in Q4 2021. Sales volume in the quarter was up by 11%. In addition, Vistin received a liquidated damage (LD) compensation of MNOK 13 in rela
- GlobeNewswire
Vistin Pharma ASA: Invitation to Q4 2022 conference call
Oslo, Norway, 10 February 2023 Vistin Pharma ASA will release its fourth quarter and preliminary 2022 results on Friday 17th of February 2023. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 17th of February at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The fourth quarter conference call will be available via web and audio through the following access points
- GlobeNewswire
Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft
Oslo, Norway, 9 December 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term industrial energy agreement with Statkraft, the leading Norwegian energy supplier. The agreement will secure a significant part of Vistin’s electricity demand on competitive terms until 2032. The agreement includes Guarantees of Origin as certification of the renewable energy supply, and starts 1.1.2023. 2022 has been very challenging for Vistin and the Norwegian industry,
- GlobeNewswire
Vistin Pharma ASA: Third quarter and YTD 2022 financial results
Oslo, Norway, 26th of October 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the third quarter 2022 Strong revenue growth in the quarter compared to last year. Revenue in the third quarter ended at MNOK 92 compared to MNOK 63 in Q3 2021, a 46% increase. Sales volume in the quarter was up by 19% compared to same quarter last year. The demand in the market for metformin from Vistin is high. However, there were still limitations on volume available for
- GlobeNewswire
Vistin Pharma ASA: Invitation to Q3 2022 conference call
Oslo, Norway, 18 October 2022 Vistin Pharma ASA will release its third quarter and YTD 2022 results on Wednesday 26th of October 2022. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Wednesday 26th of October at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The third quarter conference call will be available via web and audio through the following access points: Webca
- GlobeNewswire
Vistin Pharma ASA: Second quarter and first half 2022 financial results
Oslo, Norway, 19th of August 2022 Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter 2022 Revenue in second quarter ended at MNOK 69 compared to MNOK 67 in Q2 2021, a 3% increase. Sales volume in quarter down by approx. 11% compared to Q2’21, due to limited sales volume available. Second quarter EBITDA ended at MNOK 4.7 (Q2’21: MNOK 13.4). EBITDA unfavorably affected by limited sales volume available, start-up costs for new line, FX and re
- GlobeNewswire
Vistin Pharma ASA: Invitation to Q2 2022 conference call
Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD 2022 results on Friday 19th of August 2022. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day; Friday 19th of August at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The second quarter conference call will be available via webcast and audio through the following access points: Webcast: